ALNY240621P340000
- 0.00
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Alnylam Pharmaceuticals on Track for Record High Close -- Data Talk
Alnylam Pharmaceuticals, Inc (ALNY) is currently at $245.68, up $5.53 or 2.3% --Would be new all-time high (Based on available data back to May 28, 2004) --Would be the first record close since Dec.
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $234 to $291
On Jun 26, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $234 to $291.Morgan Stanley analyst Michael Ulz maintains with a hold
Form 144 | Alnylam Pharmaceuticals(ALNY.US) Director Proposes to Sell 2.04 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Alnylam Pharmaceuticals(ALNY.US)$ Director SCHULMAN AMY W intends to sell 8,500 shares of its common stock on Jun 25, with a total market value of approximately $2.04
Update: Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study
(Updates to reflect stock price movement in the headline and first paragraph.) Alnylam Pharmaceuticals (ALNY) shares were up more than 6% in recent Tuesday trading, a day after the company said vutris
Alnylam Pharmaceuticals Price Target Raised to $295.00/Share From $248.00 by B of A Securities
Alnylam Pharmaceuticals Price Target Raised to $295.00/Share From $248.00 by B of A Securities
Express News | TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $282
Express News | Alnylam Pharmaceuticals Are Trading Higher Amid Possible Continued Strength After the Company Yesterday Announced Topline Results From Its HELIOS-B Phase 3 Study of Vutrisiran. Also, Multiple Firms Raised Their Respective Price Targets on the Stock
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 11.6% Evercore ISI Group $210 → $260 Maintains Outperform 06/25/2024 24.9% Barclays $236 → $291
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $207 to $400
On Jun 25, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $207 to $400.Morgan Stanley analyst Michael Ulz maintains with a hold
Express News | Alnylam Pharmaceuticals, Inc. : Wells Fargo Raises Target Price to $207 From $161
Express News | Alnylam Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $250.00 From $164.00
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating
Alnylam Pharmaceuticals (ALNY) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $138 to $400. Price: 222.50, Change: -0.40, Percent C
Express News | Alnylam Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $295 From $248
Express News | Alnylam Pharmaceuticals Inc : Leerink Partners Raises Target Price to $159 From $138
Express News | Alnylam Pharmaceuticals : Barclays Raises Target Price to $291 From $236
Express News | Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $250
Express News | Alnylam Pharmaceuticals Inc : TD Cowen Raises Target Price to $282 From $260
Express News | Alnylam Pharmaceuticals Inc : Chardan Capital Markets Raises Target Price to $265 From $225